이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Juntas Adelante: A Peer-Coaching Intervention to Promote Chemoprophylaxis for HIV Prevention Among Latina Transgender Women in the Washington DC Metropolitan Area.

2026년 9월 2일 업데이트: Ana María del Río-González, George Washington University

The goal of this clinical trial is to evaluate the impact of the Juntas Adelante intervention on awareness and use of chemoprophylaxis for HIV prevention (Pre- and Post-Exposure prophylaxis, or PrEP and PEP) among Latina Transgender Women in the Washington DC Metropolitan Area. Secondary outcomes included awareness and use of Doxy-PEP (i.e., Doxycycline for prevention of Sexually Transmitted Infections - STI), and awareness of Undetectable = Untransmittable (U=U).

The main questions are:

  1. Is the Juntas Adelante intervention acceptable and feasible to implement with this population?
  2. Is participating in the Juntas Adelante intervention associated with increased awareness and use of PrEP and PEP? All participants in the study will view 5 online short videos on HIV and STI prevention and will receive up to two virtual coaching sessions with a peer coach. They will also complete a brief survey after viewing each video (5 total) and three longer surveys/interviews over the course of 3 months.

연구 개요

상세 설명

Using a community-based participatory research (CBPR) approach, we developed Juntas Adelante, an intervention to increase awareness and use of PrEP and PEP for HIV prevention among Latina transgender women in the DC metropolitan area. The Juntas Adelante intervention includes two components:

  1. Peer coaching sessions: Up to two virtual coaching sessions with another Latina transgender woman (peer coach) who has been trained to encourage dialogue around HIV prevention goals.
  2. Video mini-series: Five short informational videos covering 5 topics (one per episode): 1) Latina transgender women and HIV (duration: 2:29 min); 2) Post-exposure prophylaxis - PEP (duration: 3:49 min); 3) Pre-exposure prophylaxis - PrEP (duration: 1:58 min); 4) Doxy-PEP (duration: 3:25 min); and 5) Undetectable equals Untransmittable - U=U (duration: 3:47 min). Videos were housed into the Vimeo platform, and were embedded into REDCap surveys for distribution.

Participant recruitment and eligibility: Participants will be recruited via referrals from community members (i.e., members of the Community Council, other study participants). Eligibility criteria include: 1) Male sex assigned at birth, currently identifying as a woman, transgender woman, transgender, or transsexual, irrespective of gender transition stage; 2) identifying as Latina, regardless of country of birth; 3) being 18 years old or older; 4) living in the DC metropolitan area; 5) self-reporting HIV negative status at study enrollment 6) reporting having receptive anal and/or neovaginal sex with at least one cisgender man or transgender woman in the previous 12 months; 7) not currently using PrEP or report less than 3 months of use; 8) have access to a cellphone with internet capabilities, and 9) not planning to move from the DC metropolitan area in the next 12 months.

연구 유형

중재적

등록 (실제)

39

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20037
        • The George Washington University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  • Male sex assigned at birth, currently identifying as a woman, transgender woman, transgender, or transsexual, irrespective of gender transition stage;
  • Identifying as Latina, regardless of country of birth;
  • Being 18 years old or older;
  • Living in the DC metropolitan area;
  • Self-reporting HIV negative status at study enrollment
  • Reporting having receptive anal and/or neovaginal sex with at least one cisgender man or transgender woman in the previous 12 months;
  • Not currently using PrEP or report less than 3 months of use;
  • Must have access to a cellphone with internet capabilities,
  • Not planning to move from the DC metropolitan area in the next 12 months

Exclusion Criteria:

- Not meeting all of the inclusion criteria.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 간섭

The Juntas Adelante intervention includes two components:

  1. Peer coaching sessions: Up to two virtual coaching sessions with another Latina transgender woman (peer coach) who has been trained to encourage dialogue around HIV prevention goals. Sessions occur via Zoom, and are scheduled at the convenience of participants. In addition to HIV and STI prevention, participants may bring other topics they want to discuss during the coaching sessions.
  2. Video mini-series: Five short informational videos covering 5 topics (one per episode): 1) Latina transgender women and HIV (duration: 2:29 min); 2) Post-exposure prophylaxis - PEP (duration: 3:49 min); 3) Pre-exposure prophylaxis - PrEP (duration: 1:58 min); 4) Doxy-PEP (duration: 3:25 min); and 5) Undetectable equals Untransmittable - U=U (duration: 3:47 min). Videos were housed into the Vimeo platform, and were embedded into REDCap surveys for distribution.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
PrEP initiation/persistence and/or PEP use
기간: "Final follow up, 3 months after last coaching session"

Our primary outcome is PrEP initiation/persistence or PEP use at the 3-month follow up, defined as the combination of any:

  1. PrEP Initiation: Participants who reported having never used PrEP at baseline AND report starting PrEP between baseline and 3-month follow up OR participants who reported having ever used PrEP but were not currently using at baseline AND report re-starting PrEP between baseline and 3-month follow up.
  2. PrEP Persistence: Participants who reported using PrEP at baseline AND continued using at 3-month follow up. For daily oral PrEP, persistence is defined as still taking PrEP at 3 month follow-up. Persistence for long-acting injectable PrEP will be defined as receiving at least 1 injection since baseline visit.
  3. PEP Use: Any instance of PEP use by a non-PrEP user between baseline and 3-month follow up.
"Final follow up, 3 months after last coaching session"

2차 결과 측정

결과 측정
측정값 설명
기간
Change in PrEP awareness
기간: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about PrEP for HIV prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Baseline survey to final follow-up 3 months after last coaching session.
Change in PEP awareness
기간: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about PEP for HIV prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Baseline survey to final follow-up 3 months after last coaching session.
Change in Doxy-PEP awareness and use
기간: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about (awareness) or has used Doxy-PEP for STI prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Baseline survey to final follow-up 3 months after last coaching session.
Change in U=U awareness
기간: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about Undetectable equals Untransmittable as a treatment-as-prevention message, evaluated by comparing baseline to 3-month follow-up surveys.
Baseline survey to final follow-up 3 months after last coaching session.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 10월 1일

기본 완료 (실제)

2026년 8월 5일

연구 완료 (실제)

2026년 8월 5일

연구 등록 날짜

최초 제출

2026년 9월 2일

QC 기준을 충족하는 최초 제출

2026년 9월 2일

처음 게시됨 (실제)

2026년 9월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 2일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • IRBPH 2024.16
  • U01PS005218 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다